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Human brucellosis in Ecuador is underreported and based only on passive surveillance. 28 
Since 2008, brucellosis was removed from the list of communicable diseases in the 29 
country. Until now, the true human brucellosis picture has not yet been determined. The 30 
aim of this study was to determine the seroprevalence of the disease, to identify risk 31 
factors associated with brucellosis seropositivity in humans and to isolate circulating 32 
strains of Brucella spp. in the north-western part of Ecuador. 33 
Between 2006 and 2008, a large transect survey was conducted, based on blood 34 
sampling of people from the north-western part of Ecuador (N=3,733) together with an 35 
epidemiological inquiry. Based on three diagnostic tests used in parallel, the overall 36 
seroprevalence was estimated as 1.88% (95% C.I.: 1.48-2.38). Based on a multivariable 37 
random effects logistic regression analysis, the main risk factors associated with human 38 
brucellosis seropositivity were: contact with livestock (OR = 3.0; C.I.: 1.25 – 7.08), 39 
consumption of foetus and placenta (OR = 2.5; C.I.: 1.18 – 5.22) and involvement in 40 
activities at risk for brucellosis infection (OR =1.8; C.I.: 1.00 – 3.35). Noticeable 41 
variation in brucellosis seropositivity among humans within cantons was observed. The 42 
circulating strain was Brucella abortus biotype 4. 43 
The study emphasized that contact with livestock, consumption of foetus and placenta 44 
and occupational hazard group were all significant risk factors for the transmission of 45 
brucellosis among individuals in the north-western part of Ecuador. Alongside 46 
encouraging the launching of educational campaigns against brucellosis, especially in 47 
rural areas where 36% of the population lives, controlling this zoonotic disease in 48 
animals will directly benefit its prevention in humans especially since there is no safe 49 
and efficacious vaccine against brucellosis in humans. 50 
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 54 
Introduction 55 
Brucellosis is an infectious and contagious disease caused by Gram-negative 56 
coccobacilli, which can survive in the cells of the immune system. It has a high 57 
tendency to cause chronic infections both in humans and in cattle (Young 2007, 58 
Moriyon 2001, Torres at al. 2004, Saegerman 2010). 59 
In many countries, brucellosis is an important disease that causes serious economic 60 
losses in cattle production (FAO 2003, Guillén 2006, WHO 2006). In Ecuador these 61 
losses are estimated at 5.5 million US$ per year (Torres 2008). In humans, this zoonosis 62 
mainly leads to loses in working time and costs related to diagnosis and treatment 63 
(Bowden 1996).   64 
In Latin America, four in ten people live in areas where brucellosis is endemic in natural 65 
animal reservoirs (Alvarez 2001). However, the infection in humans is underestimated 66 
and often not reported (Dean et al., 2012) and only few reports exist concerning the 67 
identification of circulating strains of Brucella spp. (e.g. Deodato et al., 2011 ; Aznar et 68 
al., 2012; Ron-Román et al., 2012). In addition, the true incidence of this zoonosis has 69 
not yet been estimated (Lucero et al 2008; Aznar et al., 2012).  70 
In Ecuador, by means of diagnostic assays with low sensitivity, several authors have 71 
reported the presence of antibodies against Brucella spp. mainly among slaughterhouse 72 
workers: Intriago (1971) reported a prevalence of 4% (1/25), León (1979 cited by 73 
Delgado 1992) detected 10.90% (23/211), Zurita (1980, cited by Dίaz 2001) detected 74 
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23.83% (56/235) and finally Delgado (1992) mentioned a seroprevalence of 2.32% 75 
(4/173).  76 
Despite brucellosis being a communicable disease in Ecuador since 2007, the true 77 
incidence of human cases remains largely unknown. According to the Ministry of 78 
Health (MSP), only 111 human cases were reported between 1990 and 2007 (EPI-2 79 
2008), whereas, the National Institute for Statistics and Census (INEC) registered 152 80 
persons hospitalised for brucellosis between 1995 and 2007 (INEC 2008). 81 
The aim of the present work was to obtain a realistic figure of the prevalence of human 82 
brucellosis by determining the seroprevalence of antibodies against Brucella spp., and 83 
by identifying the causal agent together with possible infection-associated risk factors 84 
among people living and/or working in the north-western part of Ecuador.  85 
 86 
Materials and methods 87 
Description of the study and selection of the study region 88 
Between 2006 and 2008, a transect study was conducted, based on blood sampling of 89 
people from the north-western part of Ecuador together with an epidemiological survey. 90 
After informed consents were obtained, blood samples were taken from persons 91 
inhabiting the high-altitude or Sierra provinces such as Carchi, eastern Imbabura, 92 
eastern Pichincha and the coastal provinces such as Esmeraldas, Manabí, western 93 
Imbabura and western Pichincha.  94 
Selection of provinces was based on the high provincial-level seroprevalence of bovine 95 
brucellosis reported in Ecuador. Seroprevalence was officially estimated to be between 96 
4.0% and 10.62% in the Sierra and between 5.88% and 10.62% in the Coast (Torres 97 
2008, MAG-SESA 1999). Prior to this study, the seroprevalence was also estimated to 98 
be between 2.17% and 9.42% using the Rose Bengal Test (RB) and indirect Enzyme 99 
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Linked Immunosorbent Assay (iELISA), respectively in bovines of Santo Domingo 100 
(Pichincha) and between 1.08 and 9.73% to RB  and iELISA, respectively in El Carmen 101 
(Manabí) (Angula and Tufino, 2005). The selection of the study zone was also based on 102 
the occurrence of 41.30% (19/46) of the human cases, as reported by MSP between 103 
1997 and 2007 (EPI-2 2008) and 51.97% (79/152) of the hospitalized brucellosis 104 
patients, as reported by INEC (2008). In addition, since sheep, goats and camel 105 
populations are very small in the study area, only the link between brucellosis 106 
seroprevalence in bovines and humans was investigated. A map of the study area is 107 
shown on Figure 1. 108 
 109 
Samples 110 
After informed consent, a total of 3,733 blood samples were taken from people with 111 
different occupational hazards. A first possible high-risk group of people (n=2,444) 112 
consisted of labourers at cattle farms, slaughterhouse workers, meat and organ traders, 113 
cattle traders, veterinarians, zoo workers, teachers and students from a faculty of animal 114 
production and farm and slaughterhouse managers. A second possible low-risk group of 115 
people (n=1,289) consisted of agricultural labourers, informal traders, public servants, 116 
school and college teachers and students, house workers and transporters.  117 
Alongside collecting blood samples, other information was collected through personal 118 
face-to-face interviews. The questionnaire recorded the following information for each 119 
subject: age, sex, consumption of raw milk (yes or no), consumption of blood (yes or 120 
no), consumption of cheese (yes or no), region (Sierra or tropical), consumption of 121 
foetus or placenta (yes or no), occupational hazard group, contact with animals (yes or 122 
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no) and presence of symptoms such as pyrexia, weakness, sweating, muscle pain, 123 
backache, and headache suggestive of brucellosis (Mantur et al. 2006).  124 
Based on results of the questionnaire the people were divided into two groups, i.e. those 125 
working directly or indirectly in a slaughterhouse (n=542) and those who were not 126 
(n=3,191). The full questionnaire is available upon request from the corresponding 127 
author. 128 
 129 
Diagnostic assays  130 
Three serological assays to detect antibodies against Brucella spp. were used: Rose 131 
Bengal fast agglutination test (RBT), Wright’s Slow Agglutination Test with EDTA 132 
(SAT-EDTA) and indirect Enzyme Linked Immunosorbent Assay (iELISA). Samples 133 
were processed and analysed in the laboratory for immunodiagnosis at the International 134 
Centre for Zoonoses (CIZ) of the Central University of Ecuador (UCE).  135 
 136 
Rose Bengal fast agglutination test (RB)  137 
The RB assay was used with Bengatest
® 
antigen i.e. a concentrated suspension (4% v/v) 138 
of B. abortus Weybridge strain 19, heat and phenol (0.5%) inactivated, suspended in an 139 
acid buffer and stained with Rose Bengal. Equal quantities (30 µl) of serum and antigen 140 
were mixed in a well (4 min) on a glass plate and any degree of agglutination was 141 
considered a positive reaction.  142 
 143 
Wright’s Slow Agglutination Test with EDTA (SAT-EDTA) 144 
For SAT-EDTA, the antigen (Antigen SAW
®
, Synbiotics code # ASAW) was a 145 
concentrated suspension of B. abortus (strain 1119/3), heat and phenol (0.5%) 146 
inactivated and suspended in a phenol-buffer at 0.5%. The assay was performed as 147 
 7/38 
described by Godfroid & Boelaert, (1995) with serum dilutions of 1/12.5, 1/25, 1/50, 148 
1/100, 1/200, 1/400, 1/800, 1/1,600, 1/3,200, 1/6,400, 1/12,800 and 1/25,600 in a 149 
constant volume (100 µl) of antigen. Quantitative results were given as International 150 
Units of Agglutination (IU/ml). A value equal to or above 100 IU/ml, corresponding to 151 
75% transparency of dilution 1/50), was considered as a positive reaction. 152 
 153 
Indirect Enzyme Linked Immunosorbent Assay (iELISA)  154 
The assay was performed according to Godfroid & Boelaert (1995). Smooth B. abortus 155 
Weybridge strain 19 lipopolysaccharide (LPS) antigen was incubated on polystyrene 156 
plates for 3.5 h at 37°C and overnight at 4ºC. Plates were washed 5 times with a 157 
washing solution (NaCl 0.9% + Tween 20 at 0.01%). 158 
Then, 50 µl of 1/50 diluted serum in glycine-EDTA-Tween 80 buffer (BB) was added 159 
per well and the calibration curve was determined at dilutions 1/270, 1/540, 1/1,080, 160 
1/2,160, 1/4,320, 1/8,640. After one hour incubation at ambient temperature, the 161 
solutions were discarded, plates were washed 5 times and 50 µl conjugate (Protein G-162 
HRPO, Pirce CD47675, diluted at 1/1,500 in G - HRPO + FCS at 2%) was added to 163 
each well and left to incubate at ambient temperature for 1 hour. 164 
The same washing procedure was repeated and 100 µl substrate solution (i.e. o-PD 165 
Ortho-phenylendiamine tablets, SIGMA P-8287, one tablet of 10 mg dissolved in 25 ml 166 
citrate phosphate buffer SIGMA P-4809 + 5 µl H2O2 at 30%) was added to each well. 167 
Plates were left to incubate for 20 min in the dark at ambient temperature. Subsequently 168 
the reaction was stopped by adding 25 µl H2SO4 (2M) to each well. Optical densities 169 
(OD) were read by a spectrophotometer (STAT FX 2100), with filters between 492nm 170 
and 630nm. Mean OD values of the samples and the calibration curve were corrected by 171 
subtracting the mean BB from the mean OD. 172 
 8/38 
A cut off value, above which a sample was considered positive was set at or above 20 173 
units (U)/ml. This cut-off value was established based on local epidemiological 174 
conditions and to optimize the compromise between sensitivity and specificity (Franco 175 
et al., 2007; Gómez et al., 2008; Soudbakhsh et al., 2009). 176 
Calculation of the units was based on the reference values of the curve i.e. 1.87 U, 3.75 177 
U, 7.5 U, 15 U, 30 U, and 60 U, for dilutions 1/270, 1/540, 1/1,080, 1/2,160, 1/4,320, 178 
1/8,640 respectively. 179 
 180 
Isolation and typing of Brucella spp. (according to Alton et al. (1988)) 181 
Due to the lack of standardized procedures in Ecuador, the isolation of the causal agent 182 
was based on blood cultures - BACTEC (3 repetitions with 30 minutes-intervals) from 183 
persons with high serotitres (n=22) (Yagupsky, 1994; Cetin et al., 2007). Blood cultures 184 
were done at the “Hospital Vozandes Quito”, where they were maintained for 30 days, 185 
and after those days the cultures were considered as negatives.  186 
Isolated Brucella were identified and typified by CIZ and also by Veterinary and 187 
Agrochemical Research Centre (VAR-CERVA) as a reference laboratory using (1) 188 
macroscopic and microscopic observation of the colonies in cultures, (2) biochemical 189 
assays (oxydase, catalase and urease), (3) production of H2S, (4) CO2 growth 190 
requirement, (5) growth in stained media (thionine, basic fuchsin, safranin), (6) 191 
agglutination with mono-specific sera A and M, and (7) PCR – AMOS as described by 192 
Bricker and Halling (1994). 193 
 194 
Statistical analysis 195 
To determine the potential risk factors associated with human brucellosis sero-196 
positivity, a two stage modelling approach was used. In this approach, individuals were 197 
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considered positive if they tested positive in at least one serological test along with the 198 
presence of any of the clinical symptoms suggestive of brucellosis as previously 199 
mentioned.  200 
Firstly, a univariate analysis was performed using a random effects logistic regression 201 
model. The model used as response, the brucellosis status of the individuals (1 for 202 
positive and 0 for negative) and each risk factor or indicator variable in turn as the 203 
independent variable. The possible effects of variations in brucellosis seropositivity 204 
among the different provinces and cantons were accounted for by incorporating 205 
province and canton as a random effects in the model (VanLeeuwen et al. 2010). 206 
Secondly, variables with a p-value ≤ 0.25 in the univariate analysis were further 207 
analysed in a multivariable random effects logistic regression model. A manual forward 208 
stepwise model building approach was employed with the Akaike’s Information 209 
Criterion (AIC) as the calibrating parameter to select the final model. The model with 210 
the smallest AIC is considered to be the most appropriate model. All two-way 211 
interaction terms of the variables remaining in the final model were assessed for 212 
significance. The effects of confounding were investigated by observing the change in 213 
the estimated coefficients of the variables that remain in the final model once a non-214 
significance variable is included. When the inclusion of a non-significant variable led to 215 
a change of more than 25% of any parameter estimate, that variable was considered to 216 
be a confounder and was included in the model (Dohoo et al. 2003).  217 
The intra-class correlation coefficient (ICC), which is a measure of the degree of 218 
clustering of individuals belonging to the same province and canton, was computed 219 
(Snijders and Bosker 1999).   220 
The models were built using the xtmelogit () function in STATA, version 12, software 221 
(SataCorp LP, College station, Texas). Model selection was done using Laplacian 222 
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approximation whereas parameter estimates from the final model were obtained using 223 
Adaptive Gaussian Quadrature (Twisck 2003). The robustness of the final model was 224 
assessed by increasing the number of Quadrature (integration) points and monitoring 225 
changes in parameter estimates (Frankena et al. 2009). 226 
 227 
Ethical considerations  228 
The protocol was thoroughly reviewed and approved for ethics by the Bioethics 229 
Committee of the Biomedical Center, Central University of Ecuador. Prior to being 230 
included in the study, all participants provided informed written consent. For minors, 231 
parents/guardians provided consent on their behalf. 232 
 233 
Results 234 
Descriptive statistics 235 
A total of 3,733 persons, with a mean age of 30.03 ± 16.26 years (min=3, max=89 236 
years) were sampled in five provinces in the north-western part of Ecuador: Carchi, 237 
Imbabura, Esmeraldas, Manabí and Pichincha. Seventy people with mean age 37.86 ± 238 
14.81 years (min=10, max=79 years) reacted positive to at least one of the three 239 
diagnostic tests, representing an overall sero-prevalence of 1.88% (C.I. 1.48 -2.38). The 240 
proportion of seropositive people between groups (slaughterhouse workers versus other 241 
people) was 4.8% (26/542) and 1.4% (44/3,191), respectively. This suggests a 242 
preferential repartition of seropositive people in slaughterhouse workers (Pearson’ chi-243 
squared test = 29.4; P<0.001). 244 
The distribution of the number of individuals tested, the number and percentage of 245 
seropositives is presented in Table I. Besides teenagers and children represented 20.84% 246 
(778/3,733) of the sample with only six of them being seropositive (3 originating from 247 
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farms). The information about this sub-population is presented in the Table II. This 248 
suggests a preferential repartition of seropositive cases among older people (Pearson’ 249 
chi-squared test = 6.50; P=0.01).  250 
 251 
Risk factors for human brucellosis seropositivity based on the univariate random 252 
effects logistic regression analysis 253 
Based the results of the univariate random effects logistic regression analysis with 254 
random intercepts for both province and canton, the factors; age, sex, contact with 255 
livestock, contact with foetal secretions, consumption of foetus and placenta and 256 
involvement in activities at risk were all statistically significantly associated with 257 
human brucellosis seropositivity  (p <0.05) (Table III). On the other hand consumption 258 
of raw cow milk and consumption of fresh blood were not significant at the 5% level 259 
but since their p-values were ≤ 0.25, they were considered as potential risk factors and 260 
were thus included in the multivariate random effects logistic regression analysis.  261 
 262 
Final model based on multivariate random effects logistic regression analysis 263 
Out of the potential risk factors initially considered in the multivariate random effects 264 
logistic regression model, 3 were included in the final model (i.e., co ns umpti o n o f  265 
f o etus  and placenta,  co ntact  wi th li ves to ck and occupational hazard group). 266 
In addition, the results were not confounded by any of the variables not included in the 267 
final model. Increasing the number of quadrature points had no influence on the 268 
estimated fixed effects and the variance component parameters indicating that the model 269 
is robust. The estimated odds ratios and their 95% confidence intervals are presented in 270 
Table IV. There was no variability in brucellosis seropositivity among provinces but 271 
rather a higher variability among people within provinces.  272 
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 273 
Typifying of circulating Brucella spp. in North-West Ecuador 274 
Detailed information about persons with positive blood cultures (n=22) is given in 275 
Table V with the characteristics of the isolates, bacteriological data and PCR in Table 276 
VI and Figure 2, respectively. From three positive cases, Brucella abortus biotype 4 277 
was isolated and typified. Blood cultures were only positive for patients with higher 278 
levels of IgM antibodies (SAT-EDTA) suggesting an acute brucellosis. 279 
Retrospectively, seropositive persons (N = 70) were queried about possible symptoms 280 
related to brucellosis, a summary of the outcome based on the questionnaire is presented 281 
in Table VII. 282 
 283 
Discussion 284 
The current study aimed to provide a reliable estimation of the sero-prevalence based on 285 
the detection of antibodies against Brucella spp., the isolation and the identification of 286 
the circulating strain of Brucella spp. and the identification of possible risk factors 287 
related to the transmission and spread of brucellosis among people in the north-western 288 
part of Ecuador. 289 
 290 
Prevalence of human brucellosis in the north-western part of Ecuador 291 
In the current study an overall sero-prevalence of 1.88% (C.I. 1.48 - 2.38) was found, 292 
which may be in sharp contrast with the official data of the Ecuadorian Ministry of 293 
Health MSP i.e. only 67 cases between 2003 and 2007 (EPI-2 2008). The results of the 294 
present investigation, and additional observations described by Ron-Román et al. (2012) 295 
in humans, as well as, a seroprevalence of 2% in bovines from the same study area, and 296 
numerous isolations of Brucella sp. from different animal reservoirs (bovines and 297 
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canine) (unpublished data), suggest an underreporting of human brucellosis in Ecuador 298 
considering that 36% of the population lives in rural areas (Organización Panamericana 299 
de la Salud, 2008). 300 
 301 
Based solely on clinical symptoms, a correct diagnosis of brucellosis is not possible 302 
(Abdoel & Smits 2006; Saegerman et al. 2010) and even microbiological blood cultures 303 
are sometimes unreliable because sensitivity is too variable and too dependent on the 304 
stage of infection (i.e. acute stage) and the Brucella species concerned (Casao et al., 305 
2004). The difficulties related to the diagnosis and the often ambiguous or even absent 306 
clinical symptoms, also noted in the present study, are probably the principal reasons for 307 
the sub-notification (Serra and Godoy 2000, Agasthya et al. 2007).  308 
The non-existence of a vaccine against brucellosis in humans or the difficulty to access 309 
a safe and efficacious vaccine implies that controlling this zoonotic disease in animals 310 
will directly benefit its prevention in humans especially to improve the biosecurity. A 311 
joint work between the Ecuadorian Ministries of Public Health (MSP) and the 312 
Livestock, Aquaculture and Fisheries (MAGAP) is needed to consolidate a “One 313 
Health” initiative. 314 
 315 
Risk factors for human brucellosis in the north-western part of Ecuador 316 
The occupations that expose people to the infection are male dominated in this study 317 
region thus the apparent increased risk for infection. Several other studies have 318 
indicated gender as a significant risk factor for brucellosis (Wassif et al. 1992, Shehata 319 
et al. 2001, Mantur et al. 2007, Meky et al. 2007). The apparent elevated risk associated 320 
with older age groups could be explained simply by the fact that older people had more 321 
occasions to contract the disease (Cooper 1992, Kalaajieh 2000). Nevertheless, it is 322 
important to mention that 3 cases were also found in children below 15 years old, 323 
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confirming the findings of Guevara et al. (Guevara 2009) that children are indeed at risk 324 
and also do get the infection, e.g. due to direct or indirect contact with animals when 325 
accompanying adults handling livestock (Minas et al. 2007) or through consumption of 326 
non-pasteurised dairy products (Issa and Jamal 1999). 327 
Brucellosis is mainly an occupational disease and the multivariate analysis indicated 328 
that the odds of brucellosis seropositivity among those working in slaughterhouses were 329 
higher than those of people in the general population. This is in line with the results of 330 
other studies (Omer et al. 2002, Rahman et al. 2012). The higher sero-prevalence among 331 
slaughterhouse workers confirms the proposition that intimate contact with animals is 332 
more important than consumption of infected dairy products (McDevitt 1971). 333 
According to WHO (2006), temperatures for pasteurisation or boiling milk should be 334 
sufficiently high to eliminate bacteria and to render it fit for consumption. Nevertheless 335 
the relation between transmission of brucellosis and raw milk consumption in the 336 
present study was not statistically significant which is in line with Serra and Godoy 337 
(2000) reporting no link between presence of antibodies against Brucella spp and the 338 
unhygienic consumption of milk. This lack of an association between consumption of 339 
milk or dairy products and infection may also be due to the low number of seropositives 340 
people found in our study that consumed these products.  341 
The non-significance of the consumption of cheese squares with findings from Barroso-342 
García et al. (2007) where it was observed that the consumption of cheese is not 343 
necessarily a source of infection of brucellosis, because processing takes a few days or 344 
even weeks, affecting the number of bacteria, which was also indicated in this study. 345 
However, this information depends largely on the maturation process of each cheese 346 
considered and thus caution is recommended. 347 
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In general, the shedding of B. abortus in cows naturally infected is lower (< 10
3 
CFU/ml 348 
for several weeks but with decreasing after the partum) than for B. melitensis in small 349 
ruminants (in general > 10
3 
CFU/ml during all the lactating period) (Carpenter and Boak 350 
1928, Jouve 1952, Grilló et al. 1997, Hamdy and Amin 2002, Saegerman et al. 2010). In 351 
addition the human pathogenicity of B. abortus appears lower than B. melitensis 352 
(Godfroid et al. 2010). These elements are other possible explanations for the lack of 353 
evidence found in this study considering the link between consumption of milk and 354 
dairy products and brucellosis infection. 355 
Traditionally, milk and dairy consumption without any sanitary measures has been 356 
considered the most important route of transmission. However, recent reports stress the 357 
prominent role of transmission by direct contact with animal reservoirs (Saegerman et 358 
al. 2010, Barroso-Garcia et al. 2007, Godfroid et al. 2010).  359 
In Ecuador, a national program exists. The main objective is to obtain free brucellosis 360 
farms on a voluntary basis. In fact, this program is restricted to some farmers which are 361 
able to pay for the vaccination of calves with the B19 or RB51 vaccine, to test animals 362 
every six months and to eliminate infected animals without compensation (most often at 363 
the slaughterhouse). In addition, no control of animal movements is performed and 364 
control of dairy farms by MRT is not systematized and suffers from the lack of 365 
availability of antigen. However the milk marketed in the cities by companies is usually 366 
pasteurized. However, raw milk is sold frequently in rural and peri-urban areas.  367 
This study has not demonstrated the importance of raw milk consumption in the human 368 
brucellosis transmission, in Ecuadorian conditions. However serial isolation of B. 369 
abortus (N ~ 100) from bovine raw milk of the same area (Ron-Román et al., 370 
unpublished data) indicates that the risk exists and needs future additional investigation. 371 
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Not surprisingly, the consumption of foetus or placentas was significantly associated 372 
with brucellosis seropositivity. This alimentary tradition, though largely obsolete, is still 373 
commonly used by rural families, and even in public restaurants that offer Ecuadorian 374 
typical dishes called foetus (locally known as “ville”) or placentas (locally called 375 
“guagua mama - huagra mama”).  This meat is cooked but handling of this food item 376 
increases risk of exposure to Brucella spp. 377 
Unfortunately, the consumption of blood was not significantly associated with 378 
brucellosis seropositivity in Ecuadorian context. However, this practice can be at risk 379 
but necessitates a donor in the acute phase of brucellosis which is not frequent (Thiange 380 
et al. 1992). 381 
Education and health campaigns should target the elimination of such practices. It has 382 
indeed been observed in the population of the north-western part of Ecuador that risks 383 
related to eating habits are mostly due to a lack of basic knowledge about brucellosis 384 
and the modes of transmission.  385 
 386 
Typifying of circulating Brucella spp. in North-West Ecuador 387 
Biotyping Brucella is important for the epidemiological knowledge, since it can reveal 388 
geographical characteristics (FAO and OMS 1986) and allows a better understanding of 389 
the spread of the disease (Roux 1979). Unfortunately isolating and typing of Brucella 390 
spp. is not always possible since it requires high biosecurity laboratories and trained 391 
personnel. Furthermore, the low number of successful isolations in the present study is 392 
mainly due to the low number of patients with acute brucellosis (i.e., with high levels of 393 
IgM antibodies) and also partly due to the localisation of the bacteria in specific tissues 394 
and organs like bone marrow, cerebrospinal fluid (CSF), liver, kidneys and spleen, 395 
which renders isolation from blood very unlikely (Doganay and Aygen 2003).  396 
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In the present study 24.29% of the persons with a positive sero-reaction showed no 397 
apparent symptoms at all. This is lower than the 45.6% reported by Pila-Perez et al. 398 
(Pila-Perez 1997) and the 99% found in a retrospective study of the symptomatology by 399 
Hernández et al. (1999).  400 
Although according to Pappas et al. (Pappas et al. 2006), based only on few reported 401 
data, Ecuador was not considered an endemic country for human brucellosis, the present 402 
results, based on factual data, contradicted this statement, especially in rural areas where 403 
36% of the population lives. A recent report presented a systematic review of the 404 
scientific literature published between 1990 and 2010 relating to the frequency of 405 
human brucellosis in the world indicated that underestimation of the disease could be 406 
related to barriers in accessing health care or to case mismanagement and misdiagnosis 407 
(Dean et al. 2012). In Latin America, according to the previous report, reliable 408 
information was found only for Argentina and Mexico at sub-national level.   409 
 410 
Conclusions  411 
The absence of a National Policy and differential diagnostic tests hinders the 412 
development of surveillance and control programmes in high-risk areas for human 413 
brucellosis (especially in rural areas). It is thus difficult to have a realistic idea about the 414 
incidence of this disease. In the past, little attention was given to brucellosis in Ecuador 415 
and it is necessary to develop programmes to control (and eventually eradicate) 416 
brucellosis in the identified risk areas whereby highly sensitive diagnostic methods 417 
should be used both for humans and for animals with the objective to obtain an early 418 
warning system and to determine the correct prevalence at national level.  419 
In view of the results of this study, there is an urgent need for information campaigns, 420 
especially in rural area, about the risks involved following direct contact with livestock 421 
 18/38 
and consumption of foetus and placenta and equally about the preventive care as to 422 
avoid infection. Also, more investigations to isolate and identify the biotypes of 423 
Brucella spp. circulating in Ecuador should be followed. 424 
Finally, it is of utmost importance that evidence-based information could be given to 425 
national and international donor organisations involved with future prevention, control 426 
and research programmes on brucellosis. 427 
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Figure 2. PCR – AMOS of Brucella from blood cultures, isolated from positive 677 




Legend: MP: Molecular weight marker, B2: control Brucella abortus biotype 2, H1: Human sample 1 682 
(Ec-CIZ-Hum-1), H2: Human sample 2 (Ec-CIZ-Hum-2); *: Samples from complementary studies at 683 
CIZ; CB: Blank control. 684 
 685 
  686 
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Table I. Human brucellosis in North-West Ecuador: results of three diagnostic assays 687 
 688 
RB SAT-EDTA iELISA SLA OTH Number (%) 
- - - 516 3,147 3,663 (98.12) 
- - + 2 5 7 (0.19) 
- + - 0 0 0 (0) 
- + + 1 1 2 (0.05) 
+ - - 1 10 11 (0.29) 
+ - + 17 14 31 (0.83) 
+ + - 1 0 1 (0.03) 
+ + + 4 14 18 (0.48) 
Total   542 3,191 3,733 (100) 
 689 
Legend: RB: Rose Bengal; SAT-EDTA: Wright’s Slow Agglutination Test with EDTA; 690 
iELISA: Enzyme Linked Immunosorbent Assay; SLA: people working in a 691 
slaughterhouse; OTH: other people. 692 
 693 
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Legend: RB: Rose Bengal; SAT-EDTA: Wright’s Slow Agglutination Test; iELISA: indirect Enzyme Linked Immunosorbent Assay. 699 




















1 Pichincha Mejía 10 M farm + - boiled - - - 50 30 
2 Pichincha Mejía 16 F farm + + raw - - - 30 30 
3 Pichincha Mejía 17 M farm + - boiled - - + 80 60 
4 Imbabura Ibarra 11 F rural community - - raw - - + - - 
5 Imbabura Ibarra 10 M rural community - - boiled - - + 30 - 
6 Imbabura Urcuquí 17 F rural community + + boiled - - + 30 - 
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Table III. Distribution of seropositive results and potential risk factors for human 700 
brucellosis in the north western part of Ecuador 701 
 702 
 703 
Factor Tested Seropositives 
(%) 
Odds ratio 95% C. I. p-value 
Age (years) 
<=15 681 3 (0.4) 1 ref 0.0252 
From 16 to 45 2382 50 (2.1) 4.4 1.3-14.6  
>=46 667 17 (2.5) 4.5 1.3-16.0  
Sex       
Women 1570 22 (1.4) 1 ref 0.0415 
Men 2163 48 (2.2) 1.7 1.0-2.9  
Region      
Tropics 1185 16 (1.4) 1 ref 0.1013 
Sierra 2548 54 (2.1) 1.580.7 0.89-3.00  
Occupational 
hazard group* 
     
Low 3191 44 (1.4) 1 ref 0.0027 
High 542 26 (4.8) 2.5 1.4-4.4  
Contact with livestock 
No 724 7 (1.0) 1 ref 0.0006 
Yes 3009 63 (2.1) 3.7 1.6-8.6  
Contact with foetal secretions 
No 2159 27 (1.3) 1 ref 0.0169 
Yes 1574 43 (2.7) 1.9 1.1-3.1  
Consumption of raw milk  
No 2848 49(1.7) 1 ref 0.1886 
Yes 885 21(2.4) 1.5 0.8-2.5  
Consumption of cheese 
No 280 8 (2.9) 1 ref 0.8277 
Yes 3453 62 (1.8) 1.1 0.5-2.4  
Consumption of placenta and foetus  
No 3528 60(1.7) 1 ref 0.0169 
Yes 205 10(4.9) 2.7 1.3-5.5  
Consumption of blood  
No 3424 58(1.7) 1 ref 0.0515 
Yes 309 12(3.9) 2.0 1.0-4.0  
Province** 
Carchi 649 16 (2.5)    
Esmeralda 195 5 (2.6)    
Imbabura 1032 13 (1.3)    
Manabí 377 11 (2.9)    
Pichincha 1480 25 (1.7)    
 34/38 
Legend: ref, stands for reference category; C.I., confidence interval, *see definition in 704 
materials and methods section; ** this variable was used as a random effect in the 705 
logistic regression analysis. The p-values are based on the likelihood ratio test 706 
comparing the random intercepts-only model and the random effects model with each 707 
covariate in turn. 708 
  709 
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Table IV. Final model of risk factors associated with human brucellosis sero-positivity 710 
among people in the north-western part of Ecuador based on a multivariate random 711 
effects logistic regression analysis 712 
  713 
Ri s k f acto rs  O R P- value 95% Co nf i dence 
I nterval 
Co ns umpti o n o f  f o etus  and 
placenta 
   
No  1 - ref. 
Yes 2.5 0.016 (1.18-5.22) 
Co ntact  wi th li ves to ck    
No 1 - ref. 
Yes 3.0 0.014 (1.25-7.08) 
Occupational hazard group    
Low 1 - ref. 
High 1.8 0.049 (1.00-3.35) 
Vari ance co mpo nents  Es t i mat
e 
S . E.  
Canton 1.15 0.81 ( 0.72- 1.85) 
Province 0.0 0.29 * 
 714 
Legend: *, 95% Confidence interval was not estimated by the model; ref, stands for 715 
reference category. 716 
 717 
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Table V. Results of blood cultures from patients with high serological titres concomitant with brucellosis presumptive clinical symptoms (North-719 
West Ecuador) 720 
 721 
 722 


























1 Pichincha 28 M Farmer + + boiled - - + - 60 - 
2 Pichincha 22 M Farmer + + boiled - - + 100 60 - 
3 Pichincha 17 M Student + - boiled - - + 80 60 - 
4 Pichincha 49 F Farmer + + raw - - - 80 - - 
5 Pichincha 28 M Farmer + + boiled - - - - 30 - 
6 Pichincha 49 F Farmer + - raw - - + 100 60 - 
7 Pichincha 50 M Farmer + + boiled - - - 50 - - 
8 Pichincha 39 M Farmer + + boiled + - + 100 60 - 
9 Pichincha 41 M Veterinary lecturer + + boiled - - + 80 60 - 
10 Pichincha 26 M Farmer + + raw + - + 100 60 - 
11 Pichincha 39 M Farmer + + boiled - - + 100 60 - 
12 Pichincha 41 M Farmer + + boiled + + - 100 60 - 
13 Pichincha 39 F Slaughterhouse worker + + boiled - - + 50 60 - 
14 Carchi 42 M Slaughterhouse worker + + boiled - - + 40 60 - 
15 Carchi 55 M Transporter + - raw - - + - 50 - 
16 Carchi 50 F Slaughterhouse worker + + raw - - + - 48.6 - 
17 Carchi 66 F Slaughterhouse worker + + raw + + + 60 60 - 
18 Carchi 36 F Slaughterhouse worker + + boiled - - + 320 14.4 + 
19 Carchi 35 M Slaughterhouse worker + + boiled - - + 100 26.2 - 
20 Pichincha 27 M Veterinary student + - boiled - - + 1600 60 + 
21 Carchi 58 M Farmer + - raw - + + 800 60 + 
22 Carchi 21 M Farmer + + raw - - + 960 60 - 
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Legend: *= blood culture. 730 
     Growth on colorants 
Agglutination 
with serum 




















SHB-Cam-Nor-152 Ec-CIZ-Hum1 + + + - - + + - + 
SHB-Ay-10 Ec-CIZ-Hum2 + + + - - - - - + 
SHB-Zon-Nor-370 Ec-CIZ-Hum3 + + + + - + + - + 
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Table VII. Human brucellosis: symptoms and frequency (N = 70 inhabitants sero-731 
positive to at least one of the three diagnostic tests for brucellosis) 732 
 733 
Symptoms  Positive cases % 
Muscular pain 29 41.43 
Joint pain 25 35.71 
Fever 17 24.29 
Debility  17 24.29 
Headache 16 22.86 
Nocturnal sweating  13 18.57 
Cardiac problems 10 14.29 
Anorexia 4 5.71 
Insomnia 4 5.71 
No apparent symptoms 17 24.29 
 734 
 735 
 736 
